OPTILONE EYE DROPS 5ML

Indications

Approved Uses

Steroid-responsive inflammatory conditions of the palpebral and bulbar conjunctiva, cornea, and anterior segment of the eye.

Off-Label Uses

May be used off-label for other steroid-responsive ocular surface inflammatory conditions (e.g., vernal/allergic keratoconjunctivitis or contact lens-related inflammatory keratitis) under ophthalmologist supervision.

Dosage & Administration

Dosing by Condition

Steroid-responsive ocular inflammation: Instill 1-2 drops into the conjunctival sac 2-4 times daily; in the first 24-48 hours, frequency may be increased (commonly up to every 2 hours) based on severity, then reduce as improvement occurs.

Initial Dose

1-2 drops in the affected eye(s) 2-4 times daily. May be increased to every 4 hours for the first 24-48 hours.

Maintenance Dose

1 drop in the affected eye(s) 2-4 times daily, gradually tapered as inflammation subsides.

Children's Dosage

Children 2 years and older: same as adult dosing (1-2 drops 2-4 times daily). Not recommended in children under 2 years of age

Dose Adjustment Notes

Taper by gradually reducing dosing frequency as clinical improvement occurs; avoid abrupt discontinuation after prolonged/frequent use. If used for ≥10 days, monitor intraocular pressure (IOP) and reassess need for continuation.

How to Take

Shake well before each use (suspension). Wash hands. Instill 1-2 drops into the conjunctival sac of the affected eye(s) as prescribed. Avoid touching the dropper tip to the eye/eyelids/any surface. Close the eye gently and perform nasolacrimal occlusion (press inner corner) for ~1 minute to reduce systemic absorption. If using other eye medicines, separate by 5-10 minutes (ointments last). Remove contact lenses before use and wait at least 15 minutes before reinserting (or avoid lenses during active inflammation unless prescriber advises).

How to Prepare

Shake well before each use (ophthalmic suspension).

Side Effects

Common Side Effects

Increased intraocular pressure, temporary blurred vision, mild stinging or burning, eye irritation, feeling of a foreign body in the eye.

Side Effect Frequency

Common: transient ocular burning/stinging/irritation, blurred vision, and increased intraocular pressure; Less common/with prolonged use: posterior subcapsular cataract, delayed wound healing, secondary ocular infection, and corneal/scleral thinning/perforation risk.

Safety & Warnings

Contraindications

Hypersensitivity to fluorometholone/components; active viral disease of cornea/conjunctiva (including epithelial herpes simplex keratitis, vaccinia, varicella); mycobacterial ocular infection; fungal disease of ocular structures.

Warnings & Precautions

Monitor intraocular pressure if used for ≥10 days or if high-frequency/prolonged therapy; prolonged use may cause glaucoma/optic nerve damage and posterior subcapsular cataract; avoid use in active viral/fungal/mycobacterial ocular infection; may mask or worsen infection (use appropriate anti-infective therapy if bacterial infection present); use caution with history of herpes simplex and in corneal thinning disorders (perforation risk); shake well; avoid contaminating dropper tip.

Age Restriction

Safety and efficacy in children <2 years have not been established; use only if clearly needed under specialist supervision.

Driving Warning

Avoid Driving

Drug Interactions

Drug Interactions

Clinically significant interactions are mainly additive ocular effects with other IOP-raising agents (e.g., other ophthalmic corticosteroids) and increased risk of infection/delayed healing with concurrent immunosuppressants; CYP3A-inhibitor interaction is generally not clinically relevant for routine ophthalmic fluorometholone but may be a theoretical concern with strong inhibitors and prolonged/high-frequency use.

Interaction Severity

Clinically significant drug interactions are uncommon; use caution with strong CYP3A inhibitors (e.g., ritonavir/cobicistat) as they may increase systemic corticosteroid effects even with topical routes, and additive ocular adverse effects may occur with other topical steroids.

Food Interaction

No clinically relevant food interactions (not applicable for ophthalmic administration).

Special Populations

Pregnancy

Consult Doctor

Breastfeeding

Consult Doctor

Children

Children 2 years and older: same as adult dosing (1-2 drops 2-4 times daily). Not recommended in children under 2 years of age

Elderly

Standard adult dosing; monitor intraocular pressure closely as elderly patients may be more susceptible to steroid-induced IOP elevation

Kidney Impairment

No adjustment needed.

Liver Impairment

No adjustment needed.

Storage & Patient Advice

Preparation Instructions

Shake well before each use (ophthalmic suspension).

Missed Dose

Use the missed dose as soon as remembered; if it is close to the next scheduled dose, skip the missed dose and resume the regular schedule-do not double doses.

Stopping the Medicine

Do not stop abruptly after prolonged/frequent use; taper frequency gradually under medical supervision.

Overdose

Ocular overdose: rinse/flush the eye(s) with lukewarm water/saline; ingestion of small amounts is unlikely to cause serious toxicity-provide supportive care and seek medical advice/poison center if a large amount is swallowed or symptoms occur.

Patient Counseling

Shake well; wash hands; instill as directed without touching the tip; expect brief blurred vision-avoid driving until clear; remove contact lenses and wait ≥15 minutes before reinsertion (or avoid during active inflammation unless advised); space other eye drops by 5-10 minutes; do not use longer than prescribed and do not stop abruptly if used frequently/prolonged-taper per prescriber; seek care urgently for worsening pain, redness, discharge, photophobia, or vision changes; do not share the bottle. Discard after the in-use period per local labeling/pharmacy policy (commonly 28 days after opening if not otherwise specified).

Monitoring Requirements

Check intraocular pressure if treatment continues for ~10 days or longer; with prolonged/repeated courses, perform slit-lamp examination to monitor for cataract formation, corneal thinning/ulceration, and superinfection (including fungal/HSV) if symptoms worsen.

Pharmacology

Mechanism of Action

A synthetic corticosteroid that suppresses ocular inflammation by inducing lipocortins (phospholipase A2 inhibitory proteins), reducing arachidonic-acid-derived mediators (prostaglandins, leukotrienes) and other inflammatory signaling.

Onset of Action

Relief may begin within hours; noticeable improvement often within 24-48 hours in steroid-responsive inflammation.

Half-Life

Unknown/Not established for ophthalmic fluorometholone (systemic half-life after ocular dosing not reliably reported).

Bioavailability

Systemic absorption is minimal after ophthalmic administration; most effect is local in ocular tissues, and systemic bioavailability is low (further reduced by nasolacrimal occlusion).

Excretion

Unknown/Not well characterized for ophthalmic fluorometholone; any systemically absorbed fraction is expected to be eliminated mainly as metabolites via renal excretion with some biliary/fecal contribution (class effect of corticosteroids).

Protein Binding

Unknown/Not established for fluorometholone ophthalmic suspension.

Product Information

Available Dosage Forms

Ophthalmic suspension.

Composition per Dose

Each 1 mL of ophthalmic suspension: fluorometholone 1 mg (0.1%)

Generic Availability

Yes

OTC Alternatives

No OTC equivalent corticosteroid eye drop alternative; symptomatic OTC options (e.g., lubricants/antihistamine-mast cell stabilizer drops) are not therapeutic equivalents for steroid-responsive inflammation.

Target Organ

Eye

Preservative Free

No

Legal Disclaimer - Al Mujtama Pharmacy The product information provided is derived from verified pharmaceutical references and is intended for general health education only. It is not a substitute for professional medical advice, diagnosis, or treatment. Al Mujtama Pharmacy assumes no legal or medical liability for: Any therapeutic decision made based on the information displayed without consulting a licensed physician or pharmacist Any discrepancy between the information provided and the product's package insert or SFDA guidelines Any misuse of medication resulting from personal interpretation of the content displayed Important notice: Drug formulations and instructions may vary between production batches. Always rely on the leaflet included inside the product packaging you have, and consult your pharmacist or physician before starting, adjusting, or discontinuing any medication. By using this content, you acknowledge that you have read this disclaimer and agree that Al Mujtama Pharmacy bears no liability arising from reliance on this information as a substitute for direct medical consultation. Your health is a trust - always consult your doctor first.